EMYRIA LIMITED — Board/Management Information 2021

Aug 19, 2021

ASX Announcement

20/08/2021

Emyria appoints expert neuropharmacologist for MDMA-analogue development program

Highlights:

• Emyria has engaged renowned neuropharmacologist, and former Head of Psychopharmacology at UWA, Dr. Mat Martin-Iverson to help evaluate a library of novel MDMA-analogues, recently optioned to Emyria exclusively

• Dr. Martin-Iverson has over 35 years of experience studying amphetamines and other psychostimulants

• Dr. Martin-Iverson will assist in the screening of the existing library and help advise in the creation of new compounds to help expand the library

• Emyria’s MDMA-analogue program has the potential to result in the commercialisation of multiple novel psychedelic-assisted therapies and treatments for other neurological disorders

Emyria Limited (ASX: EMD) (Emyria or the Company), a data-backed drug development and care delivery company, has engaged world-leading neuropharmacologist, Dr. Mat Martin-Iverson to advise over the screening and expansion of Emyria’s recently announced MDMA-analogue program. ( See announcement 05 August 2021)

Dr. Martin-Iverson has over 35 years of experience studying and researching the effects of amphetamines and other psychostimulants. Dr. Martin-Iverson has authored over 160 publications with a particular focus on dopamine-related effects including its role in drug addiction, schizophrenia, Parkinson’s disease, attention and motivation.

Notable career highlights::

• Former Head of Psychopharmacology Laboratory, School of Biomedical Sciences, University of Western Australia

• Professor or Associate Professor at UWA since 1995

• Head of Pharmacology 2004-2006; 2016-Jan 2021

• Consultant Pharmacologist, Statewide Department of Neurophysiology (Graylands Hospital) North Metropolitan Health Services - Mental Health, 2002-2017

• Member of the WA Psychotropic Advisory Committee to the Chief Psychiatrist and WATAG from 2004-2019

1

==> picture [137 x 40] intentionally omitted <==

Emyria’s Managing Director, Dr. Michael Winlo , said: “We are delighted to be working closely with Dr. Martin-Iverson as we evaluate and expand our unique library of MDMA-analogues.

We believe Dr. Martin-Iverson's unique expertise and deep knowledge of amphetamines will help us identify promising compounds, as well as to design new ones, to develop promising novel psychedelics and new treatments for neurological disorders.”

Dr. Martin-Iverson , said: “I’m excited to work with Emyria, and Dr. Matt Piggott’s team at UWA, to screen and expand this library of unique compounds that have the potential to become new treatments for patients in need.”

Emyria’s MDMA discovery pipeline

Emyria recently secured exclusive rights to a library of more than 100 novel MDMA analogues from the University of Western Australia creating a unique drug-discovery pipeline for Emyria.

The library of compounds was developed by a highly regarded research group led by medicinal chemist, Dr. Matt Piggott. Dr. Piggott and his team have been developing MDMA analogues, and exploring their therapeutic potential, for more than 10 years.

As part of the initial phase of work, Emyria will screen and expand the existing library in order to identify families of patentable compounds with the greatest promise as new psychedelic-assisted therapies and treatments for other neurological disorders.

Emyria will lead the global patent strategy, already underway, as well as further clinical development and commercialisation of this under explored research space

Program has the potential to result in the commercialisation of multiple, novel, CNS-active compounds to help treat patients with major unmet needs.

This announcement has been approved and authorised for release by the Managing Director of Emyria Limited.

For further information:

Dr. Michael Winlo Lexi O’Halloran Managing Director Media/Investor Relations 1300 436 363 + 61 (0) 404 577 076 mwinlo@emyria.com lexi@janemorganmanagement.com.au

Andrew Williams Media Relations +61 (0) 412 614 125 andreww@proflemedia.com.au

2

==> picture [137 x 40] intentionally omitted <==

About Emyria (www.emyria.com)

Emyria Limited is a clinical drug development and care delivery company. Emyria’s Treatments target large unmet needs and are focused on obtaining approval (“registration”) with major global regulators. Emyria’s treatment development programs are informed by insights generated from extensive analysis of Emyria Data - deep, ethically-sourced clinical evidence that is gathered with patients across Emyria’s independent clinical services ( Emerald Clinics - www.emeraldclinics.com.au)

Emyria Data provides deep treatment insights and is therefore a source of unique IP, strategically designed drug development and personalised care programs.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

3